Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $51.56 USD
Change Today +2.54 / 5.18%
Volume 2.2M
ISIS On Other Exchanges
As of 4:00 PM 08/27/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

B. Lynne Parshall Esq., J.D.

Chief Operating Officer, Director and Member of Agenda Committee,Isis Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 35 board members in 2 different organizations across 5 different industries.

See Board Relationships
As of Fiscal Year 2014


Ms. B. Lynne Parshall, Esq., J.D. has been the Chief Operating Officer of Isis Pharmaceuticals, Inc. since December 2007 and served as its Corporate Secretary. Ms. Parshall served as Secretary at Isis Pharmaceuticals, Inc. since November 1991. Ms. Parshall served as an Executive Vice President since December 1995, Chief Financial Officer from June 1994 to January 2013, Senior Vice President from February 1993 to December 1995 and Vice President from November 1991 to ...

Read Full Background

Corporate Headquarters*

2855 Gazelle Court
Carlsbad, California 92010

United States

Phone: 760-931-9200
Fax: --

Board Members Memberships*

Chief Operating Officer, Director and Member of Agenda Committee
Director, Chairman of Audit Committee and Member of Nominating & Governance Committee


Harvard University
Stanford University Law school

Other Affiliations*

Annual Compensation*

Total Annual Compensation$1,130,924

Stock Options*

Restricted Stock Awards$655,325
All Other Compensation$24,023
Exercised Options96,652
Exercised Options Value$3,709,315
Exercisable Options38,552
Exercisable Options Value$1,878,883
Unexercisable Options133,181
Unexercisable Options Value$4,319,926
Total Value of Options$9,908,124
Total Number of Options268,385

Total Compensation*

Total Annual Cash Compensation$1,154,947
Total Short Term Compensation$1,130,924
Other Long Term Compensation$679,348
Total Calculated Compensation$3,232,043
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ISIS:US $51.56 USD +2.54


Ron Cohen M.D.Founder, Chief Executive Officer, President and Director
Acorda Therapeutics, Inc.
James A. Schoeneck Chief Executive Officer, President and Director
DepoMed Inc.
George Frederick Wilkinson Chief Executive Officer, President and Director
Impax Laboratories Inc.
Stephen R. Davis J.D.Interim Chief Executive Officer, Chief Financial Officer, Chief Business Officer and Executive Vice President
ACADIA Pharmaceuticals Inc.
John M. Maraganore M.D., Ph.D.Chief Executive Officer and Executive Director
Alnylam Pharmaceuticals, Inc.
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ISIS PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at